Whole-brain 3D MR fingerprinting brain imaging: clinical validation and feasibility to patients with meningioma
Magnetic Resonance Materials in Physics, Biology and Medicine · 2021-10 · 34 (5) · 697-706
DOI: 10.1007/s10334-021-00924-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magnetic Resonance Materials in Physics, Biology and Medicine, online erschienen am 04.05.2021. Verfasst von Thomaz R Mostardeiro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, MN, USA. thomaz.r.mostardeiro@gmail.com. Hauptthemen laut MEDLINE: Meningeal Neoplasms, Meningioma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Individualized Medicine, Mayo Clinic.
Abstract (Originalsprache)
Purpose
MR fingerprinting (MRF) is a MR technique that allows assessment of tissue relaxation times. The purpose of this study is to evaluate the clinical application of this technique in patients with meningioma. Materials and methods A whole-brain 3D isotropic 1mm 3 acquisition under a 3.0T field strength was used to obtain MRF T 1 and T 2 -based relaxometry values in 4:38 s. The accuracy of values was quantified by scanning a quantitative MR relaxometry phantom. In vivo evaluation was performed by applying the sequence to 20 subjects with 25 meningiomas. Regions of interest included the meningioma, caudate head, centrum semiovale, contralateral white matter and thalamus. For both phantom and subjects, mean values of both T 1 and T 2 estimates were obtained. Statistical significance of differences in mean values between the meningioma and other brain structures was tested using a Friedman’s ANOVA test.
Results
MR fingerprinting phantom data demonstrated a linear relationship between measured and reference relaxometry estimates for both T 1 ( r 2 = 0.99) and T 2 ( r 2 = 0.97). MRF T 1 relaxation times were longer in meningioma (mean ± SD 1429 ± 202 ms) compared to thalamus (mean ± SD 1054 ± 58 ms; p = 0.004), centrum semiovale (mean ± SD 825 ± 42 ms; p < 0.001) and contralateral white matter (mean ± SD 799 ± 40 ms; p < 0.001). MRF T 2 relaxation times were longer for meningioma (mean ± SD 69 ± 27 ms) as compared to thalamus (mean ± SD 27 ± 3 ms; p < 0.001), caudate head (mean ± SD 39 ± 5 ms; p < 0.001) and contralateral white matter (mean ± SD 35 ± 4 ms; p < 0.001)
Conclusions
Phantom measurements indicate that the proposed 3D-MRF sequence relaxometry estimations are valid and reproducible. For in vivo, entire brain coverage was obtained in clinically feasible time and allows quantitative assessment of meningioma in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Mayo Clinic, Rochester, MN, USA. thomaz.r.mostardeiro@gmail.com.
- Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Förderung
- Center for Individualized Medicine, Mayo Clinic
Zitieren
APA
Mostardeiro, T. R., Panda, A., Witte, R. J., Campeau, N. G., McGee, K. P., Sui, Y., & Lu, A. (2021). Whole-brain 3D MR fingerprinting brain imaging: clinical validation and feasibility to patients with meningioma. Magnetic Resonance Materials in Physics, Biology and Medicine, 34(5), 697-706. https://doi.org/10.1007/s10334-021-00924-1
Vancouver
Mostardeiro TR, Panda A, Witte RJ, Campeau NG, McGee KP, Sui Y, et al. Whole-brain 3D MR fingerprinting brain imaging: clinical validation and feasibility to patients with meningioma. Magnetic Resonance Materials in Physics, Biology and Medicine. 2021;34(5):697-706. doi:10.1007/s10334-021-00924-1
BibTeX
@article{Mostardeiro2021,
author = {Mostardeiro, Thomaz R and Panda, Ananya and Witte, Robert J and Campeau, Norbert G and McGee, Kiaran P and Sui, Yi and Lu, Aiming},
title = {Whole-brain 3D MR fingerprinting brain imaging: clinical validation and feasibility to patients with meningioma},
journal = {Magnetic Resonance Materials in Physics, Biology and Medicine},
year = {2021},
volume = {34},
number = {5},
pages = {697--706},
doi = {10.1007/s10334-021-00924-1}
}
EUVIMED